You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Men's Issues Articles
Popular Men's Issues Articles
Highly Recommended Men's Issues Articles
Send a link to this page to your friends and colleagues.
British researchers say that testosterone replacement therapy for type 2 men with low testosterone levels could reduce their death rate significantly. Over the course of a six-year study by the University of Sheffield, only 8.6 percent of low-testosterone subjects who were given replacement therapy died, compared to 20 percent of low-testosterone subjects who did not receive the therapy.
The study involved 587 type 2 men who were divided into three groups:
• Men with normal testosterone levels (Nine percent of this group died over the course of the study)
• Men with low testosterone levels who were not treated with replacement therapy (20 percent of this group died over the course of the study)
• Men with low testosterone levels who received replacement therapy (8.6 percent of this group died over the course of the study, slightly fewer than in the normal testosterone-level group)
The study results confirm a suspicion that low testosterone levels, which occur in many men with type 2 diabetes, can be linked to an increased risk of death. However, these results also suggest that it may be possible to offer a fairly simple treatment to counter that risk. Further studies on a larger scale will be needed to confirm the findings.
The researchers presented their findings in early April at the Society for Endocrinology BES 2011 meeting in Birmingham, UK.
2 comments - May 2, 2011
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.